Premium
Interleukin‐1B (IL1B) and interleukin‐6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia
Author(s) -
Ennas Maria G.,
Moore Patrick S.,
Zucca Mariagrazia,
Angelucci Emanuele,
Cabras Maria G.,
Melis Massimo,
Gabbas Attilio,
Serpe Roberto,
Madeddu Clelia,
Scarpa Aldo,
Cocco Pierluigi
Publication year - 2008
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.843
Subject(s) - single nucleotide polymorphism , genotype , allele , immunology , medicine , population , chronic lymphocytic leukemia , allele frequency , gastroenterology , biology , gene , genetics , leukemia , environmental health
Abstract Common polymorphisms in genes encoding for cytokines implicated in the inflammatory response and Th1/Th2 balance might play a role in the development and prognosis of chronic lymphocytic leukaemia (CLL). To test the hypothesis, we investigated 13 single nucleotide polymorphisms (SNPs) in nine of such genes in a population‐based case‐control study, conducted in the Italian region of Sardinia in 1999–2003. Forty incident CLL cases and 113 population controls were available for study. The following SNPs were selected: IL1A‐889 C > T, IL1RN 9589 A > T , IL1B‐31 C > T , IL1B‐511 C > T , IL2‐384 T > G , IL6‐174 G > C , IL6‐597 G > A , IL10‐1082 A > G , IL10‐3575 T > A , TNF‐308 G > A , LTA‐ 91 A > C , LTA 252 A > G and CARD15 nt1007 . After adjusting by age and gender, individuals homozygous for the IL1B‐511 T allele run a lower risk of CLL (OR = 0.1, 95% CI 0.0, 0.8, p = 0.032), while risk showed a 4.5‐fold increase associated with the genotype homozygous for the IL6‐174 C allele (OR = 4.5; 95% CI 1.1, 19.3, p = 0.041). Individuals homozygous for the IL6‐174 C allele and carrying the homozygous IL1B‐511 C allele showed an 11‐fold increase in CLL risk (OR = 11.4, 95% CI 1.9, 69.4, p = 0.008). None of the other interleukin SNPs evaluated showed any association with CLL risk. Large multicentre pooled studies are warranted, achieving the statistical power required to confirm whether IL6 and IL1B gene polymorphisms might play a role in CLL development and prognosis, as well as the null associations herein reported. Copyright © 2008 John Wiley & Sons, Ltd.